Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.63 |
| ▸ | HRH2 | P25021 | 1/20 | 0.63 |
| ▸ | HRH1 | P35367 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13437928 | 0.96 | HRH3 (0.62) | HRH3HRH2HRH1MAOBKCNH2 | |
| SCHEMBL13437929 | 0.82 | HRH3 (0.43) | HRH3HRH2HRH1MAOBKCNH2 | |
| SCHEMBL736582 | 0.81 | HRH3 (0.62) | HRH3KCNH2CHRM2SLC6A2ADRA1A | |
| SCHEMBL491861 | 0.80 | HRH3 (0.93) | HRH3HRH2HRH1MAOB | |
| SCHEMBL1776447 | 0.80 | HRH3 (0.71) | HRH3HRH2HRH1MAOBKCNH2 | |
| SCHEMBL20652676 | 0.80 | HRH3 (0.67) | HRH3HRH2HRH1MAOBKCNH2 | |
| SCHEMBL4672757 | 0.80 | HRH3 (0.62) | HRH3HRH2HRH1MAOBKCNH2 | |
| SCHEMBL16024725 | 0.80 | HRH3 (0.62) | HRH3HRH2HRH1MAOBKCNH2 | |
| SCHEMBL20385617 | 0.80 | HRH3 (0.62) | HRH3HRH2HRH1MAOBKCNH2 | |
| SCHEMBL12128607 | 0.79 | HRH3 (0.67) | HRH3HRH2HRH1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-7615550-B2 | Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | GLAXO GROUP LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| US-7615550-B2 | Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | GLAXO GROUP LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| US-7615550-B2 | Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | GLAXO GROUP LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| US-20060025404-A1 | Substituted piperazines,(1,4) diaszepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1567511-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004035556-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025404-A1 | Substituted piperazines,(1,4) diaszepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists | HRH3, HRH4, HRH2 | HRH3 1/4885HRH2 3/4885HRH1 4/4885 |
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | HRH3, HRH4, HRH2 | HRH3 1/4885HRH2 3/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.